GENELUX Corp (GNLX)

Latest Insider Confidence Score

2026Q1

48.3
Bearish

Company insider confidence (by quarter)

2023Q1 2026Q1

Largest shareholders

Insider Role (last 12 mo) Shares held Filed at
Szalay Aladar 10% Owner 2,813,760 Sep 13, 2024
Thomas John Director 492,784 Dec 2, 2025
Zindrick Thomas CEO 478,800 Aug 29, 2025
Scigalla Paul — 163,883 Jan 25, 2023
Cappello Joseph Chief Technical Officer 142,500 Aug 29, 2025

Recent buy/sell transactions

Exec date Filing date Insider Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Mar 2, 2026 Mar 3, 2026 Thomas John Director Sell 44.4 -10,000 -2.03% ✓ $29K
Jan 2, 2026 Jan 7, 2026 Litten Jason Chief Medical Officer Neutral 52.5 - 0.00% ✗ -
Jan 7, 2026 Litten Jason Chief Medical Officer Neutral 52.5 - 0.00% ✗ -
Aug 21, 2025 Dec 11, 2025 Yu Yong SVP, Clinical Development Sell 26.3 -4,192 -2.79% ✗ $16K
Aug 21, 2025 Dec 11, 2025 Zindrick Thomas CEO Sell 22.5 -17,182 -3.09% ✗ $66.4K
Aug 21, 2025 Dec 11, 2025 Cappello Joseph Chief Technical Officer Sell 26.3 -3,706 -2.32% ✗ $14.4K
Aug 21, 2025 Dec 9, 2025 Smalling Ralph Head of Regulatory Sell 27.5 -2,332 -3.28% ✗ $8.7K
Dec 1, 2025 Dec 2, 2025 Thomas John Director Sell 45.0 -10,000 -1.99% ✓ $50K
Sep 1, 2025 Sep 3, 2025 Zindrick Thomas CEO Neutral 52.5 - 0.00% ✗ -
Sep 1, 2025 Sep 3, 2025 Yu Yong SVP, Clinical Development Neutral 52.5 - 0.00% ✗ -
Sep 1, 2025 Sep 3, 2025 Smalling Ralph Head of Regulatory Neutral 90.0 +10,000 16.40% ✗ -
Sep 1, 2025 Sep 3, 2025 Cappello Joseph Chief Technical Officer Neutral 52.5 - 0.00% ✗ -
Aug 27, 2025 Aug 29, 2025 Thomas John Director Neutral 82.5 +22,283 4.64% ✗ -
Aug 27, 2025 Aug 29, 2025 Zindrick Thomas CEO Neutral 90.0 +361,200 187.19% ✗ -
Aug 27, 2025 Aug 29, 2025 Smalling Ralph Head of Regulatory Neutral 90.0 +26,230 75.46% ✗ -
Aug 27, 2025 Aug 29, 2025 Smither John W Director Neutral 90.0 +22,283 42.27% ✗ -
Aug 27, 2025 Aug 29, 2025 Yu Yong SVP, Clinical Development Neutral 90.0 +101,480 209.00% ✗ -
Aug 27, 2025 Aug 29, 2025 Mirabelli Mary Director Neutral 90.0 +22,283 43.69% ✗ -
Aug 27, 2025 Aug 29, 2025 Tyree James L Director Neutral 90.0 +22,283 48.66% ✗ -
Aug 27, 2025 Aug 29, 2025 Cappello Joseph Chief Technical Officer Neutral 90.0 +107,500 205.68% ✗ -
Jul 1, 2025 Jul 2, 2025 Groen Eric General Counsel & Secretary Neutral 52.5 - 0.00% ✗ -
Jul 2, 2025 Groen Eric General Counsel & Secretary Neutral 52.5 - 0.00% ✗ -
Jun 6, 2025 Jun 24, 2025 Thomas John Director Neutral 27.5 -25,000 -4.95% ✗ -
May 12, 2025 May 13, 2025 Ryder Sean General Counsel Sell 26.3 -4,475 -8.59% ✗ $13.1K
May 12, 2025 May 13, 2025 Zindrick Thomas CEO Sell 26.3 -10,764 -5.32% ✗ $31.4K
May 12, 2025 May 13, 2025 Yu Yong VP, Clinical Trial Operations Sell 26.3 -5,579 -10.48% ✗ $16.3K
May 12, 2025 May 13, 2025 Cappello Joseph VP, Pharmaceutical Development Sell 26.3 -4,737 -8.31% ✗ $13.8K
May 12, 2025 May 13, 2025 Smalling Ralph Head of Regulatory Sell 27.5 -1,259 -3.50% ✗ $3.7K
Mar 14, 2025 Apr 17, 2025 Smalling Ralph Head of Regulatory Neutral 90.0 +4,172 13.10% ✗ -
Mar 14, 2025 Apr 17, 2025 Cappello Joseph VP, Pharmaceutical Development Neutral 90.0 +13,350 30.58% ✗ -
Mar 14, 2025 Apr 17, 2025 Yu Yong VP, Clinical Trial Operations Neutral 90.0 +13,350 33.48% ✗ -
Mar 14, 2025 Apr 17, 2025 Ryder Sean General Counsel Neutral 90.0 +10,708 25.87% ✗ -
Mar 14, 2025 Apr 17, 2025 Zindrick Thomas CEO Neutral 90.0 +30,339 17.65% ✗ -
Jan 31, 2025 Feb 3, 2025 Pulisic Matthew CFO Neutral 52.5 - 0.00% ✗ -
Feb 3, 2025 Pulisic Matthew CFO Neutral 52.5 - 0.00% ✗ -
Aug 1, 2024 Dec 31, 2024 Thomas John Director Neutral 52.5 - 0.00% ✗ -
Aug 1, 2024 Dec 31, 2024 Mirabelli Mary Director Neutral 52.5 - 0.00% ✗ -
Aug 1, 2024 Dec 31, 2024 Smither John W Director Neutral 52.5 - 0.00% ✗ -
Aug 1, 2024 Dec 31, 2024 Tyree James L Director Neutral 52.5 - 0.00% ✗ -
Dec 30, 2024 Dec 30, 2024 Tyree James L Director Sell 27.5 -3,460 -7.03% ✗ $8.5K
Dec 18, 2024 Dec 20, 2024 Smalling Ralph Head of Regulatory Neutral 90.0 +15,525 95.12% ✗ -
Dec 18, 2024 Dec 20, 2024 Ryder Sean General Counsel Neutral 90.0 +22,000 113.47% ✗ -
Dec 18, 2024 Dec 20, 2024 Yu Yong VP, Clinical Trial Operations Neutral 90.0 +29,000 266.81% ✗ -
Dec 18, 2024 Dec 20, 2024 Cappello Joseph VP, Pharmaceutical Development Neutral 90.0 +29,000 197.91% ✗ -
Dec 18, 2024 Dec 20, 2024 Zak Lourie S. CFO Neutral 90.0 +41,650 102.08% ✗ -
Dec 18, 2024 Dec 20, 2024 Zindrick Thomas CEO Neutral 90.0 +134,500 359.90% ✗ -
Dec 16, 2024 Dec 18, 2024 Zindrick Thomas CEO Sell 26.3 -14,315 -27.70% ✗ $33.5K
Dec 16, 2024 Dec 18, 2024 Zak Lourie S. CFO Sell 27.5 -2,103 -4.90% ✗ $4.9K
Dec 16, 2024 Dec 18, 2024 Smalling Ralph Head of Regulatory Sell 27.5 -2,510 -13.33% ✗ $5.9K
Dec 16, 2024 Dec 18, 2024 Cappello Joseph VP, Pharmaceutical Development Sell 26.3 -6,300 -30.07% ✗ $14.7K
Oct 18, 2024 Oct 21, 2024 Scigalla Paul Chief Medical Officer Neutral 52.5 - 0.00% ✗ -
Sep 26, 2024 Tyree James L Director Neutral 58.8 - 0.00% ✓ -
Sep 12, 2024 Sep 13, 2024 Szalay Aladar 10% Owner Sell 22.5 -64,857 -9.68% ✗ $171.7K
Sep 11, 2024 Sep 12, 2024 Tyree James L Director Sell 42.5 -1,730 -3.51% ✓ $4.5K
Sep 9, 2024 Sep 11, 2024 Szalay Aladar 10% Owner Sell 22.5 -75,143 -10.09% ✗ $196.6K
Sep 3, 2024 Sep 6, 2024 Szalay Aladar 10% Owner Sell 22.5 -42,818 -5.44% ✗ $89.6K
Aug 28, 2024 Aug 30, 2024 Szalay Aladar 10% Owner Sell 20.0 -265,552 -25.21% ✗ $554.4K
Aug 23, 2024 Aug 27, 2024 Szalay Aladar 10% Owner Sell 22.5 -91,630 -8.00% ✗ $200.3K
Aug 1, 2024 Aug 5, 2024 Tyree James L Director Neutral 90.0 +39,541 407.22% ✗ -
Aug 1, 2024 Aug 5, 2024 Mirabelli Mary Director Neutral 90.0 +39,541 317.34% ✗ -
Aug 1, 2024 Aug 5, 2024 Thomas John Director Neutral 85.0 +39,541 8.49% ✗ -
Aug 1, 2024 Aug 5, 2024 Smither John W Director Neutral 90.0 +39,541 300.24% ✗ -
Feb 19, 2024 Jul 8, 2024 Zindrick Thomas CEO Neutral 90.0 +34,584 89.61% ✗ -
Feb 19, 2024 Jul 8, 2024 Zak Lourie S. CFO Neutral 85.0 +5,072 7.71% ✗ -
Feb 19, 2024 Jul 8, 2024 Smalling Ralph Head of Regulatory Neutral 85.0 +2,723 9.28% ✗ -
Feb 19, 2024 Jul 8, 2024 Cappello Joseph VP, Pharmaceutical Development Neutral 90.0 +15,218 265.35% ✗ -
Feb 19, 2024 Jul 8, 2024 Yu Yong VP, Clinical Trial Operations Sell 91.3 +8,369 334.76% ✗ $14.5K
Feb 19, 2024 Jul 8, 2024 Ryder Sean General Counsel Sell 91.3 +6,710 13.70% ✗ $11.7K
Feb 19, 2024 Jul 8, 2024 Jewett Caroline Head of Quality Sell 43.8 -206 -0.32% ✗ $10.5K
May 29, 2024 Jun 7, 2024 Tyree James L Director Neutral 90.0 +6,250 180.64% ✗ -
May 29, 2024 Jun 7, 2024 Smither John W Director Neutral 90.0 +6,250 90.32% ✗ -
May 29, 2024 Jun 7, 2024 Thomas John Director Neutral 67.5 +2,500 0.54% ✗ -
May 29, 2024 Jun 7, 2024 Mirabelli Mary Director Neutral 90.0 +8,000 179.37% ✗ -
May 29, 2024 Jun 7, 2024 Yu Yong VP, Clinical Trial Operations Neutral 90.0 +2,500 100.00% ✗ -
May 29, 2024 Jun 7, 2024 Zindrick Thomas CEO Neutral 90.0 +200,000 1365.09% ✗ -
May 29, 2024 Jun 7, 2024 Smalling Ralph Head of Regulatory Neutral 90.0 +1,250 10.36% ✗ -
May 29, 2024 Jun 7, 2024 Ryder Sean General Counsel Neutral 90.0 +10,000 1748.25% ✗ -
May 29, 2024 Jun 7, 2024 Zak Lourie S. CFO Neutral 90.0 +31,250 100.00% ✗ -
May 13, 2024 May 15, 2024 Szalay Aladar 10% Owner Sell 22.5 -35,966 -3.05% ✗ $130.4K
May 7, 2024 May 9, 2024 Szalay Aladar 10% Owner Sell 22.5 -19,944 -1.66% ✗ $75.3K
Apr 29, 2024 May 1, 2024 Szalay Aladar 10% Owner Sell 22.5 -59,999 -4.76% ✗ $193.9K
Apr 22, 2024 Apr 24, 2024 Szalay Aladar 10% Owner Sell 22.5 -44,395 -3.40% ✗ $155.6K
Apr 16, 2024 Apr 18, 2024 Szalay Aladar 10% Owner Sell 20.0 -71,420 -5.19% ✗ $256.2K
Dec 15, 2023 Dec 18, 2023 Yu Yong VP, Clinical Trial Operations Sell 20.0 -32,535 -100.00% ✗ $428.2K
Dec 13, 2023 Dec 14, 2023 Tyree James L Director Sell 22.5 -9,000 -72.23% ✗ $119K
Dec 13, 2023 Dec 14, 2023 Thomas John Director Sell 22.5 -9,000 -1.90% ✗ $120.4K
Dec 7, 2023 Dec 8, 2023 Yu Yong VP, Clinical Trial Operations Sell 20.0 -36,800 -53.08% ✗ $436K
Nov 21, 2023 Nov 22, 2023 Yu Yong VP, Clinical Trial Operations Sell 22.5 -18,665 -21.21% ✗ $191.6K
Nov 17, 2023 Nov 21, 2023 Yu Yong VP, Clinical Trial Operations Sell 22.5 -18,135 -17.09% ✗ $210.4K
Oct 25, 2023 Oct 26, 2023 Szalay Aladar 10% Owner Sell 40.0 -5,704 -0.41% ✗ $110.6K
Oct 23, 2023 Oct 25, 2023 Szalay Aladar 10% Owner Sell 20.0 -49,987 -3.49% ✗ $998.4K
Oct 24, 2023 Oct 25, 2023 Yu Yong VP, Clinical Trial Operations Sell 37.5 -5,200 -4.67% ✓ $99.4K
Oct 16, 2023 Oct 16, 2023 Thomas John Director Sell 47.5 -3,333 -0.70% ✓ $69K
Oct 10, 2023 Oct 11, 2023 Yu Yong VP, Clinical Trial Operations Sell 37.5 -5,200 -4.67% ✓ $114.5K
Oct 5, 2023 Oct 10, 2023 Szalay Aladar 10% Owner Sell 30.0 -14,251 -0.99% ✗ $355.2K
Oct 3, 2023 Oct 4, 2023 Szalay Aladar 10% Owner Sell 17.5 -75,690 -4.97% ✗ $1.9M
Oct 2, 2023 Oct 4, 2023 Jewett Caroline Head of Quality Neutral 52.5 - 0.00% ✗ -
Sep 27, 2023 Sep 29, 2023 Szalay Aladar 10% Owner Sell 30.0 -13,546 -0.88% ✗ $330.7K
Sep 25, 2023 Sep 27, 2023 Szalay Aladar 10% Owner Sell 17.5 -42,263 -2.68% ✗ $1M
Sep 26, 2023 Sep 27, 2023 Yu Yong VP, Clinical Trial Operations Sell 37.5 -5,200 -4.67% ✓ $122.5K